Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02346526 · ClinicalTrials.gov registry record · Phase 2
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02346526: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02346526 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02346526, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to look for markers of how Ra-223 improves the lives of men with prostate cancer. This study makes use of Ra-223 in the standard FDA-approved way, but adds non-standard testing in an attempt to gain insight about how the drug works and how best to track patients who are receiving the drug.
Interventions
- PROCEDURE CT scan
- PROCEDURE Blood Tests
- PROCEDURE FACBC PET/MRI in a subset of participants
- DRUG Radium-223 dichloride
- PROCEDURE bone scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-04 |
| Est. Completion | 2020-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02346526
The ClinicalTrials.gov registry entry for NCT02346526 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which CT scan is the first listed.
NCT02346526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02346526 about?
NCT02346526 is a clinical study titled "A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer". The purpose of this study is to look for markers of how Ra-223 improves the lives of men with prostate cancer. This study makes use of Ra-223 in the standard FDA-approved way, but adds non-standard testing in an attempt to gain insight about how the drug works and how best to track patients who are ...
What is the current status of trial NCT02346526?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2015-04. Estimated completion is 2020-12.
What interventions are being tested in trial NCT02346526?
The interventions under investigation include: CT scan (PROCEDURE), Blood Tests (PROCEDURE), FACBC PET/MRI in a subset of participants (PROCEDURE), Radium-223 dichloride (DRUG), bone scan (PROCEDURE).
Who is sponsoring clinical trial NCT02346526?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.